MK-3475-057: A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects With High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

February 18, 2019
Cancer - Bladder, Cancer - Colorectal
Principal Investigator: Clara Hwang, MD
Cancer, Bladder cancer, Phase 2, Phase II, Pembrolizumab, High risk